In short
Fast Money Podcast Episode Summary - The Most Important Charts In The Market… Plus Tracking Weight Loss Drug Supply (6/4/24)
Episode Overview
- Podcast Title: Fast Money
- Air Date: June 4, 2024
- Host: Melissa Lee
- Notable Guests: Tim Seymour, Karen Feineman, Dan Nathan, Guy Adami
In this episode, the traders discuss crucial charts that can indicate the future direction of the stock market amidst recent market stagnations. They also review the implications of weight loss drug shortages, particularly those related to GLP-1 medications, and how a telehealth company is addressing the issue.
Key Themes and Discussions
Market Analysis
- Current Market Status: Major indices (Dow, NASDAQ, S&P) experienced slight gains, but trading has been in a holding pattern since May.
- Important Charts: Each trader identifies what they believe to be the most telling chart in the market.
Traders' Chart Picks
- Tim Seymour - Consumer Discretionary ETF (XLY)
- Insight: Signs of consumer spending collapse indicated by recent performance of major discretionary brands (Amazon, Tesla, Home Depot, etc.).
- Historical Context: XLY peaked in November 2021, coinciding with rising inflation and interest rates.
- Concern: Weakness in consumer spending may lead to broader economic issues.
- Karen Feineman - KRE (SPDR S&P Regional Banking ETF)
- Insight: KRE's poor performance suggests underlying issues in regional banks, particularly concerning rising interest rates and commercial real estate.
- Possibility of Trouble: Small and regional banks are crucial for small businesses; their weakness may signal broader economic concerns.
- Dan Nathan - Market Cap Weighted SPX vs. RSP
- Insight: Narrowing market breadth with a focus on major players like NVIDIA and Microsoft indicates potential risk if these stocks falter.
- Concern: Disparity in performance between market cap weighted and equal-weight indices could foreshadow market adjustments.
- Guy Adami - NVIDIA
- Insight: NVIDIA is central to market sentiment; however, the rapid growth may not be sustainable.
- Warning: Companies may begin to close the gap with NVIDIA's competitive advantage, especially regarding profit margins.
Weight Loss Drug Supply
- Rho's GLP-1 Supply Tracker: A telehealth company has launched a tool to help patients locate supplies of GLP-1 drugs amidst shortages.
- Functionality: Allows patients to crowdsource supply information and report shortages directly to the FDA.
- Market Demand: Increasing applications of GLP-1 drugs beyond obesity to areas such as depression and Alzheimer's.
Key Takeaways
- Consumer Spending Concerns: Indicators suggest a potential downturn in consumer discretionary spending, which is critical for economic health.
- Banking Sector Weakness: The status of regional banks raises alarms about credit availability to small businesses.
- Tech Stock Sentiment: Heavy reliance on a few tech giants, particularly NVIDIA, poses risks if market dynamics shift.
- Healthcare Innovations: The telehealth sector is actively addressing supply chain issues in the pharmaceuticals space, particularly for high-demand weight loss drugs.
Conclusion The episode underscores the importance of tracking specific market indicators and sectors to assess the overall economic climate. Insights into consumer behavior, banking health, and emerging healthcare technologies provide valuable perspectives for investors navigating today's market challenges.
For full details on the discussion and stocks mentioned, tune in to the full podcast episode on CNBC or visit [Fast Money's website](http://fastmoney.cnbc.com).
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:03Live from the Nasdaq Markets 8 in the heart of New York City's Times Square, this is Fast Money. Here's what's on tap tonight. Sideways, stocks, major markets, and a holding pattern over the last few weeks. But some charts may hold the true key to where we are heading next. The traders lay out their picks for what they're watching right now. And tracking supply, how one company is trying to help patients navigate shortages in the GLP-1 drug supply. And how the pharma giants are managing their own supply chains. Plus, dueling calls on Tesla. Will the bull or bear win this battle? Easy come, easy go for India's stock markets.
0:34and why Roaring Kitty's options bet on GameStop is more complicated than it may seem. I'm Melissa Lee, come to you live from CEO of B at the NASDAQ on the desk tonight. Tim Seymour, Karen Feinemann, Dan Nathan, and Guy Adami. The major markets managing to eke out gains at the end of the session with the Dow, NASDAQ, and S &P all now positive so far for the week, but it hasn't been a steady climb over the last few weeks with the S &P trading in a pretty tight range from the start of May. So with the big indices not giving us a clear sign of where they are heading next, We thought it'd be a good time to ask the traders to see what they are seeing as the most important chart in the market.
1:07The most important chart of the market. This is a tough game, by the way. It is. I mean, you know, what's the timeline? It's more like an assignment. There's so much to do here. But, Tim, what is yours? Well, I went with the XLY, which is the consumer discretionary ETF. And I went with it because I think we're starting to finally see the consumer collapse. And I think we're seeing it in a handful of names. And I think we even got some jolts data around what's going on with payroll. We'll get to that later in the show. If you look at where the XLY peaked, you can see that I think it was November of 21, really right about when the Fed started to get into their heavy duty assault on inflation and interest rates, whether it was too late or not.
1:48To that point, off the covid lows, it outperformed the S &P by 25 percent. What you can see in this second chart is this is the ratio chart. This is essentially XLY relative to SPY. And you can see we're making new lows. And you have to look under the hood in most ETFs. If you look under this hood, you can see the biggest is Amazon. The second biggest is Tesla. They kind of offset each other. You could make an argument if this was Tesla knocking it down, OK. But then you get into Home Depot. Then you get into Nike. Then you get into TJX. Then you get into Starbucks. We've heard from every one of these players.
2:18And I just think it's, you know, again, what's the most important chart for the market? it's certainly for a time and place. But as we think about what's been so strong, it's been the consumer. I'm worried about discretionary spend. And we've heard it from a lot of different types of discretionary spend, this earnings. And from a GDP perspective, the consumer is the most important part of that measure. I think that's a great chart. I mean, Amazon, 24%, Tesla, 13%. Throw McDonald's in there. Throw CMG in there, which is only probably 4%. But that's obviously done really well. And I'm with Tim on this one.
2:50It's telling a story without question. And you throw lows. I mean, there's a lot to be concerned about without question. And if obviously Amazon were to roll, that would roll in a significant way. For me, if you're asking me if we're still playing the game. You were asked. I was? Well, yes. You seem very excited to bring to the American public your chart. No, I'm not that excited. Well, I'm excited. You are, because I didn't even really prompt you. Every Wednesday is an exciting or hump day you get across the... Huh? The KRE, Melissa Lee. And if you look at the KRE... Listen, again, I'm not calling for banks to explode or...
3:21But KRE has not been trading particularly well now for quite some time. This is something that probably made its all-time high sometime in 2022. We know what happened in 23, and it bounced. However, we're nowhere close to its prior all-time high with an S &P that's obviously within earshot of is. There's a lot to be concerned about here. And if you think about it, if small and regional banks are sort of the lifeblood for small and medium-sized businesses, I think it's trying to tell a bit of a story here. So as the market continues to go higher, KRE sort of waning here is not particularly encouraging.
3:53One of the things that had been ailing KRE is the exposure to commercial real estate, the concerns there with rates coming down and potentially, you know, coming down even more with a Fed cut closer rather than farther away. Isn't that better? Yeah, you would have thought that. And I think that the price action of large money centers, of home builders, of regional banks, especially, you know, we just had, you know, 10-year come in 30 basis points in, what, three, four trading days. You would have thought those stocks or those sectors would have been trading a lot better. They haven't been. We've been talking about that a little bit.
4:22So, again, you know, we were making arguments of why the banks are okay. They're benefiting when rates were going higher. And, you know, obviously we think that they're going to do better if they were lower, especially with those sorts of exposure, but it doesn't seem to be playing out. Do you want to talk about banks or do you want to talk about anything? Okay. So, actually, I did one trade today. I got out of Morgan Stanley and increased my Citibank bet. And so we're a little five weeks away, I guess, from earnings. And this one being the cheapest on the book metric makes it interesting to me.
4:55And I like weeks from earnings. Yeah. Yeah. I mean, I mean, I had to go through, right? I know. Just in the tail end for banks again, guy. Yeah. I mean, just like that. A lot of those will probably, they'll be reporting Friday, July 13th is probably, or the 12th, actually. Okay. July 12th is when we start again. Bankerings will start. It was April 12th when they all reported. Right. So, yeah. So, so, so, uh, diminishing your Morgan Stanley position. To zero. To zero. Yeah. Which is a, is a, is what? What does that say? It was, it had done nicely on that. Remember when they had that investigation and that, that seemed like a compliance nightmare.
5:32Marin. I thought it was going to weigh on them a lot. And yet they put out good numbers. Their asset management business is doing nicely. And I also think that there is a tailwind in the amount of capital markets business that there will be. And so that sounds like the bullish case. It was. And they got excited. The market took it up north of 100. Right. And that was surprising. So I sold it. I don't know. Ninety eight and change today. Citibank, I think, has a lot of those elements as well, but is cheaper. It doesn't have the asset. It is not seen as having the asset management that a Morgan Stanley does.
6:07I'll give you that. It does have banking business, does have other businesses, and the valuation, I thought, was really cheap. So that was what I did in the bank space. I don't think it's a bad time for banks. If your book is not where Bank of America is, I think a lot of good things can happen. And we haven't seen credit quality. It's ticked up a little bit, but it is nowhere remotely close to problematic right now. and the economy is doing okay. So I like the valuation, particularly when the market is more expensive. So Karen Self, would you rather effectively? I did. What she can do. She's allowed to do.
6:38If I even look at you wrong, I get in trouble. Well, within her own portfolio, sure, she can do whatever she wants. Excellent point by you. What would you do? I agree with her on the sitting. We've talked about this. You know, we've said that if it just gets to 75 % of book value with a$99.50, it's a$75 stock. And I'll stand by that. We've said it for a while. I think it closed, what, 61 and change. So I think there's room here. I think she's right to do that. Morgan Stanley has her own sort of, I don't know, idiosyncratic issues, I guess. But Citibank here, if you look very quietly at the chart, I mean, it's been sort of grinding higher for quite some time now.
7:10You're a holder, Citibank. Citibank is my largest bank position and has been also through appreciation. And I guess I think about the Morgan Stanley and the asset management business, which is obviously such a major part of the story now. We've come through such an extraordinary period. Any weakness in the markets and any weakness in terms of asset flows is something to worry about for some of these names. But right now, it's obviously been a tailwind. Karen, what is your most important chart? OK, see, here's the thing, though, about the assignment. What's wrong with you? She's already hedging.
7:40I am already hedging because, you know, it's funny. We have Carter and he looks at and learns everything from the chart. And I look at the chart and go, really, what can we get from this? And he looks at valuation fundamentals and go, really, that's going to tell you something? We just want to know what you think is the most sure. I picked NVIDIA because as the breadth is not going wider, it's actually narrowing, I think that so much of the sentiment in the market right now is just wrapped up in this name and everything that's seen as a peripheral to this name. So I think this is the most important show.
8:08I think that's a fine pick for me. Nothing wrong with that. Of course you do. You're almost apologetic. I think you nailed that one. Well, thank you. I think they didn't pick NVIDIA. I'm devastated. What do you think of NVIDIA? I mean, I think it's a good point. You're also concerned about the brain. Mine's a segue. I'll just get into mine. I mean, so mine is the SPY. No, no, but you guys can elaborate on both of them at once. I mean, mine is the market cap weighted SPX versus the RSP, which is obviously the equal weight. And it's for basically the same reason that you're talking about. It's Microsoft.
8:44It's NVIDIA. It's Meta. It's Amazon. It's Google. It's Lilly. Okay? And it's also JP Morgan. when you think of like some of the top holdings. Now, obviously, Apple is not participating right now. It's basically flat on the year. Tesla's falling out. It's down 30 % or so. But when you think about the market cap weight and you think about the enthusiasm, there really are two megatrends that are kind of wrapped up in that, right? So it's obviously generative AI, but then Lilly has had massive appreciation. So at some point, if you were to look at a ratio chart, you'd see that, you know, the SPY or the SPX, however you're looking at it, is really pushing it here.
9:15You know what I mean? And so it wouldn't take much, to your point, about sentiment with one name like NVIDIA or the adjacent names like Microsoft, and then you start saying, oh, well, Amazon doesn't really have it great, and Google hasn't done a good job with their rollouts. You know what I mean? You would start second-guessing all of those the way that investors second-guess Dell, Supermicro, and Hewlett-Packard last week. So this is just a concern of yours. Should the gap close and you think the S &P 500 should fall? Correct. And the last point I'll just say is the S &P 500 is up 30 % off its October lows.
9:44The RSP is only up 22%. So that demonstrates that outperformance from the market cap weighted. It's so hard, though, to say, you know what, I'm not going to own NVIDIA anymore. If you're in it, it's difficult. Yeah, it's hard. I did sell some calls. Especially after the rock star speech yesterday at Precomputex. And you've got two new chips. You've got, I don't know, Vera. I don't know. Ruben. Ruben. But it's a road map. I understand. But the road map tells you about$50 trillion in industrial and hard assets. It's the next industrial revolution, AI style. So if you think about some of these industrial companies, and this is something that different people on our desk who have come on our desk.
10:23I know Savita's talked about this. Industrial companies that have actually become a lot more profitable because of the dynamic with AI and some of the things here. So until NVIDIA, and I realize it could be it could be at almost any day, except for the fact that the entire chip space is, you know, that is the new commodity space. And they continue to make new highs. So Karen's probably won the game today. Well, I think, though, I mean, the NVIDIA. Video calls are really pumped. A July, a regular expiration, July 19th, 1200 went out at 5866. So the stock's got to go to 1258 just to break even. That seems rich to me.
10:59We'll see what this stock split does. I have a sense this is sort of up on partially that. I don't know, Dan. Well, one thing I wanted to say about what Tim just said about the Computex and the roadmap, right? So we're still on H100. So anybody who's buying these GPUs are still talking about that. And then now we got a lot of excitement about Blackwell. And now there's additional excitement about Rubin in 2026. If you think that it's a straight line from here to 2026, you know what I mean? Like, I just don't see that, right? I agree that there's high potential for speed bumps ahead. But at the same time, when they guided higher on Q2, it was on the old chip.
11:35I mean, the difference in the increase in revenue is on the old chip, so people are still ordering. So the transition of this. And if Tim started out by saying the XOI and consumer spending, you said the consumer is about to crash. If the consumer is about to crash, that means. Stan's trying to paint me into a corner now. You did say it.
11:55It starts with the consumer. All right. Then corporations start cutting costs again. That means headcount reduction. That means all of these SaaS companies and all these things, they start losing licenses from heads. Right. They pull back on R &D and CapEx and all that sort of stuff. and then you have a downward cycle in enterprise spending. And so that's why it's not a straight line. And all these companies, like, you know, I listen to Justin Wang. I saw what he said. There was a lot of word salad in there. I'm telling you, and I'll get the quotes from it. He was talking about CEO math and all this sort of stuff and 98 % cost reductions and 97 % energy reductions.
12:29It sounds like nonsense. Here's my question. Can you have a world, though, where enterprise spend gets cut back or whatever, It's a period of austerity comes and companies still spend on a relative basis more on AI than other parts. So you'll just see continued pressure on the CRMs, which we've already heard about from earnings. Right. So they are defensive on a relative. But then there'll be pricing. There'll be pricing pressure like like like it just will be. And, you know, like so you're going to have all these other folks coming into the market. They're going to compete on price. And again, I mean, like if you guys think it's a straight line from here to there because this.
13:01I don't know who said straight line. I didn't hear straight line anywhere. I talked about what I heard yesterday was recognizing a new addressable market for where this could go for industrial, for physical assets, for industries where physics are actually a big part of kind of where the revolution will come. So the issue with NVIDIA is that it's doubled every, you know, it doubles every six months. That's the problem. Their earnings are keeping pace with it for now. We all know it can't grow at this pace. To say that it's the most important stock in the market, we do that all the time. We know what it is.
13:32But semis right now as a group have not shown that they're ready to break down. The old saying, you know, your margins are our opportunity type. And that's going to at some point that now I understand they have a huge head start in video. But my sense is companies will start to close the gap, I think, faster than the market anticipates. And those 77 percent margins or so, you know, enjoy it while it lasts, because I don't think it's going to remain stay here for very much longer. All right. Meantime, Treasury yields continuing to slide today with the 10-year hitting its lowest level since early April.
14:03The latest move coming as investors await Friday's jobs report. But where are rates going from here? For some answers, we bring in the man with lots of charts, the chart master, Carter Braxton Wirth. Hey, Carter. Hi. Yeah, I mean, look, I'm in the lower rates camp. And yet maybe there's no camp to be in before we look at the charts. The truth is higher hasn't happened. Lower hasn't happened. We're just stuck here in the mid-fours. This chart that you see on the screen, we're right now exactly where we were in October of 2022. That's 20 months ago. At that point, we had just spiked from two and a half to four, three in three months, and higher for longer became a mantra.
14:45But it's not been higher for longer. It's been no change. And so the question is, ultimately, I think we're in the peaking process. These lines would suggest, to my eye anyway, that we're going to break trend. Let's look at a few more iterations. It's all the same chart, one after another. But if you look at the next one, you'll see here that 20 months, despite that slight blip above 5%, interest rates are not higher, not on the 10-year, and there's just no way around that. And it's a good lesson for all of us when something becomes a mantra to typically consider suspect. Let's keep going. Next chart.
15:18And they're all the same. It's the same time frame, but just drawn a different way. The down arrow was a judgment. That's mine. Other people are thinking, and I have a lot of clients that push back on the note again today saying, you know, when the buyers step away, the Chinese and the Japanese and the federal government, we're going to have a big problem. The bond vigilantes are coming. I can't speak to that, but my hunch is lower. Let's keep going. I think I've got one or two more ways to draw the lines here. It's all the same chart. We broke that minor trend that you see today. Again, 4.32, lower than where we were in October of 2022.
15:53It's June of 2024. I think we might have one more. It's all the same chart. It's just different ways to depict the situation. Falling back below that horizontal line is not good if one is bullish of yields or thinking yields are going higher. Maybe one more, I guess, there is, and then that's it. And so I think we break this formation. I'm a buyer of long-dated treasuries. Hey, Carter. It's Karen. So if we break that line, where do you think the next stop is? Well, see, that might be the seduction, right? Maybe it isn't meaningful. One could say, well, my goodness, you're thinking 2%, 3.25%. It's very possible that the whole rate conversation, right, isn't productive in the sense that maybe this is the proper level for 10-year treasuries and that the work of Cap-M, right, and dividend discount models and discounting cash flow should disregard this and that the securities analysts, the portfolio managers, should go back to the job of trying to figure out two to three-year future cash flow and discounting and putting a price target and not extrapolating 7 % on the 10-year, 3 % on the 10-year, because it turns out the 10-year is the same level it was two years ago.
17:08But as to how much lower, I think we're going into the high threes. Carter, it's Tim. It's hard for me to argue that, especially if we get some of the economic turnaround, that rates aren't going to come lower. And at least that's not the first move. And I do think there's this whole setup of less central bank buying. I do think there's a deficit to finance that's a very different story. How can you argue that rates haven't gone higher since July of 2020? And I realize you can pick spots since, you know, you can find spots in October were of 22 or back in 22. And I'm picking a spot, too. Like, I'm picking a low spot.
17:39I recognize I'm buying in the low spot. But I can draw a trend line all the way there that has not been violated from July of 2020. So I don't want to get here and try to get out there and die on the hill if I think rates have to go over 5 % tomorrow. But I think rates have consistently crept higher with periods of a lot of volatility. Well, they have. I mean, we know that from the low of COVID, when the cost of 10-year money was almost zero, we're up meaningfully. We're up 5x from those levels. But the point of this exercise, at least as I think, that spike high in October of 2022, we'd essentially gone from 2.5 % to 4.5%.
18:15That was the low for the market. The S &P at that point in October of 2022 was down 27%. We were in a bear market. The Nasdaq 100 was down 37%. But the extrapolators at the time, that's when higher for longer became, well, my God, if we've just gone from 2.5 % to 4.5%. What about 6.5 %? And it turned out that was completely not right. And it's not about being wrong and right. It's just that rates really are not meaningfully higher. Yes, over the past three, five years, they are. But is, and there's no way around this, is 10-year money at 4.5%, is that a bad thing? Is that a bad thing for valuation?
18:49Of course it's not. In any other era, that would be considered nirvana. All right. Carter, thanks. Carter Braxton Worth, the Chartmaster. Meantime, we've got an earnings alert here we want to get to on HP Enterprise, shares of the Enterprise software company ripping higher on a top and bottom line B powered by demand for AI servers. Also, the company's personal systems business seeing growth for the first time in eight quarters. The after hours gains bring the stock to their highest level since March. We are up by 13 and a half percent. A little bit different from what we saw from Dell. Yes, a little bit different.
19:21Also, more enterprise as well. So, I mean, this one, not yet, Dan. But no, better than Dell. Dell, I mean, I really went through it and looked at it again, looked at it more on Dell. And I do think they're going to work their way through it. But definitely more compression on margin than I would like. Yeah, go back and look at Hewlett last week. It had a huge gap after a big run. It gave most of it back over the next couple of days or so. So, again, I think these are kind of hard things to buy on the breakouts here. because I think there's not a heck of a lot of confidence, maybe for the current quarter, given the guidance that some of these companies are giving, but beyond that.
19:57Reasonable on valuation. I think the full-year guide might disappoint people a little if you look at the magnitude of the beat and then the subsequent guide. With that said, go back to, if we can do a longer-term chart, 2018 we were at basically$20. We're right up against a prior high. It's going to be interesting to see tomorrow if we do break out or if it fails at this prior level. All right, we've got another news alert here on New York Community Bank, some changes to the board. Contessa Brewers got the details. Contessa. Melissa, another twist in the drama that is New York Community Bank this year.
20:28The parent company of Flagstar Bank announced a change in the executive chairman of the board. Alessandro D 'Anello is out. Joseph Odding, who currently serves as the president and CEO, will take on the chair role. Additionally, D 'Anello was stay on, we're told, as director and advisor to Odding, according to the company news release. He briefly served as CEO from February 23rd through April 1st after Moody's downgraded NYCB to junk territory. Last year, it had acquired Signature Bank. It got hit in the commercial real estate book, and the company hit with a slew of analyst downgrades. Shares are off 69 % year to date, and now we'll have the CEO coming on to take over the chairman role, Melissa.
21:13All right, Contessa, thank you. Contessa Brewer. Karen, are you still in this? I am. I am. I just view this as not so much. I mean, this was the, I believe this was the CEO over which that other guy from the board resigned and said, well, you know, actually, I'm not certain that was him. I don't think this is a big deal. I think this is who Mnuchin wants to be in the chairman role. And so that's who it's going to be. So maybe my KRE thing wasn't that far off base there. You want to reassess your Karen Wins thing or no? You mean in terms of the best chart? This is all. This is KREs and New York Community Bank.
21:49I mean, all this regional bank stuff still seem to be cropping inside up, but no. Karen Wins. This is a minor. It's not a big deal, but I think the whole NYCB thing is it is now an option with life. And when you have life and you have volatility on a relatively big book, good things can happen or you can lose all your money. Coming up, Lulu Lowdown. Shares still, excuse me, in downward dog as investors braced for earnings tomorrow. What to expect and how the rest of retail is faring ahead. Plus, markets in India reversing after yesterday's big win. What the election results in that country could mean for stocks.
22:23Don't go anywhere. Fast Money's back into.
Read the full transcript
22:31Welcome back to Fast Money. Lulu shares trading near 52-week lows as the retailer gears up to report earnings tomorrow. That stock is down 40 % this year already. Other retailers under pressure as well lately, Nordstrom, Macy's, Dollar Gen, Williams-Sonoma, just some of the names well in the red today. So to Tim's point, maybe the consumer is under some duress guy or at least just examples of where the weakness are because there are other retailers that are doing okay. I think in some cases, it's definitely a tell on the consumer. I think in other cases, and Tim's pointed this out, I mean, Lululemon, when that growth stops, and we've seen this with all kinds of specialty retailers over the years, that's when things go really bad.
23:08We had an analyst on recently who thinks the base or a potential bear case is$150. I think his base case is$240 or so. And it's hard to argue with that given some of the margin contraction we've seen and some of the growth, basically, retraction, I guess, for lack of a better word, or just growth slowdown that we've seen. With that said, there are places to be. I mean, Walmart works here without question. And even Costco at some point on the back of the sell-off of the earnings release is going to work as well. You know, it's interesting. Taking stock of Q1 earnings season and some of the guidance, I feel like, and maybe this is purely anecdotal, but Karen, I know you listen to a lot of calls.
23:43Tim, you listen to a lot of calls. Guy, you do too. I feel like I heard that the consumer is resilient a lot more than I heard that the consumer is weakening. You know what I mean? From you? I find this surprising. No, no. We're talking about the calls. Oh, okay. We're talking about all the conference calls, okay? No, but I just said, again and again, we heard it from the money center banks. We heard it from a lot of these big box guys, you know, and maybe some of them had some other issues. I mean, it's not things that we're hearing about from Lulu or Nike, but maybe that's more specific to the inventory that they have and the price point and that sort of thing.
24:15So, again, I'm just saying that purely anecdotal. You know, until the consumer rolls over, Tim, you know what I mean? Brassus, what did we say? Well, it's not we. It was you. Yeah. Well, part of the issue, though, for Lulu is Lulu. And Lulu's got a competitive dynamic out there. They're at peak margin. They're in a place where you could make an argument that also you've seen some of the best of at least that U.S. saturation. They have to look to other markets, whether they're going to be hurt by the shift to wide leg bottoms and denim guy. They already have been. They missed the trend. But I think the story here, and this is the story that I would stretch across discretionary, which is what I said.
24:55Yes, I think the consumer is running out of gas in terms of – and we haven't heard it across all groups. And Walmart, by the way, has taken market share. Walmart behaves like a tech stock. Walmart's up 35 percent this year. Walmart's a story of a company that's invested in technology and better margins. Lulu is a story where the margins are coming down. And that's really the story, I think, whether that's across discretionary, we'll see. I think there's pressure. There is pressure. I mean, but looking at the price to earnings ratio of Lulu, which I didn't think would be here, which is now 21 and change.
25:26Are you getting I am getting tempted. So I don't you know, they do report tomorrow afternoon. So I don't really have a strong feeling about how they're going to do on earnings tomorrow. We've all heard about pressure on the consumer, but also competitive pressures that they haven't faced before, whether it's Viore or Aloe. So probably not an athlete, although they had good numbers. So I am somewhat intrigued by that in that I feel like this deserves a premium multiple, right? We know they've had some stumbles, but I do. I actually think it's interesting. There's a lot more fast money to come. Here's what's coming up next.
26:04A big reversal in Indian markets as a narrow election win causes stocks to sell off. what the tight results could mean for policy in the country and your investments abroad. Plus, the weight loss drug space is surging. And as popularity grows, so do shortages. How one company is helping customers track supply. You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.
26:39Welcome back to Fast Money. The INDA India ETF reversing course after hitting an all-time high yesterday. The fund erasing nearly a month's worth of gains and seeing its worst day since September 2021. The pullback coming as election data shows incumbent Prime Minister Narendra Modi's majority may not be as strong as it looked based on Monday's exit polls. Investors had been hoping that strong majority would be able to push through pro-business and forward investment reforms, which now may take much more work. He's got to get the votes of his allies to come on board in order to pass some of these things.
27:08Yeah, there's going to have to be some more populist spending. And Modi has gone out of his way to tell you we're going to get you inside the 5.6 deficit on the budget to GDP. And it's been a story of market reform. So if you've been investing in India, it's been one of the great stories. It's since March of 23. It's up 42 or 3 percent. It's been grinding higher. It's effectively what China used to be, right? You're not getting 8 % growth out of China. You're certainly not getting the demographics that you are out of India. And that's the story. It's not cheap. It's a case where I think you have opportunities here.
27:41ICICI Bank is the second largest position in my Idebo ETF. I actually think this is a story where you want to buy growth. You want to overpay for stories that are working, especially in emerging markets. This pullback doesn't really concern me. But this is what you get with emerging markets. And this is the day after Mexico. We heard the shine bomb had a crazy majority that actually could allow her to push through the type of, you know, call it popular spending that would concern investors. And you see how quickly things can change in terms of the macro. India is not changing overnight. It's not cheap.
28:13This pullback is a chance for people to take profits. But I think Modi is someone I would put my money behind. In terms of the reasons why he didn't get that strong majority that was expected, it's because of these underlying issues like poverty, high unemployment. I mean, are those things going to drag down the growth prospects for India? And so, you know, they're not going to be as good. Seemingly, they could. These populist issues exist in every country in the world. Inflation is higher. There's a lot more stretch. I would say weaker oil prices, weaker commodity prices. These are things that are great for India.
28:47They have more inflationary problems than probably any other economy of this size. And again, it's the fifth largest economy in the world. How are you feeling about getting rid of some of your Mexico yesterday? No bueno. I mean, I wasn't really that I didn't want to be that long because I'm not very comfortable with what this is going to be. So I'd like to see if it would bounce a little bit more. But to me, this changes the game for a while. All right. All right. Coming up, tracking to Zepatai, how one telehealth company is helping customers find their weight loss drugs amid a raft of shortages.
29:13We've got the details next and a tug of war on Tesla. Analysts out with conflicting calls on the ED maker. We'll lay out their cases. And if you should say plugged into the day, Fast Money's back in tune. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
29:38Welcome back to Fast Money. Stocks closing in the green today with the Dow jumping 140 points. The S &P and Nasdaq both squeezing out small gains as well. All three indices now up this week. Some more after hours action. Crowd strike shares higher after a beat on the top and the bottom line. The company also raising Q2 revenue and EPS guidance. Stock is up 7%. Meantime, as shortages of popular weight loss drugs drag on, one telehealth company is out with a new tool to help patients access their doses. Rose GLP-1 Supply Tracker launched last week. It's a free site allowing anyone to find supply information by drug, dose, size, and pharmacy location in real time.
30:15Patients also set up alerts to find out when doses become available in their area. Joining us for more is Zach Ritano, co-founder and CEO of Rho. Zach, welcome to Fast Money. Thanks so much for having me. So how is this powered? Is this crowdsourced? It is crowdsourced. So the tool does, we're super excited about it, does two very specific things. The first is that it lets patients crowdsource supply by sharing where they found it, and it'll notify any patient who said they need supply within 100 miles in real time. Second thing it does is it lets patients report shortages to the FDA in 30 seconds or less.
30:47And so we released it a week ago. In the last week, we've had over 25 ,000 submissions of shortages. We've had well over 1 ,000 people report supplies. We've been able to notify patients across the country to increase access to these drugs and help navigate the shortages. So is this only reporting shortages of actual name brand GLP-1 drugs? That's right. Patients will report the drug dose that they need in the zip code, and then patients will report the pharmacy that they found that drug in, and we will notify a patient with the pharmacy name, link, phone number, to be able to transfer to that pharmacy.
31:20In theory, does this help the FDA keep track of how deep the shortage is, and therefore keep terzeptide and semaglutide on the shortage list so that they can be compounded? I think the main intention with this, and we've been in touch with the agency, and they've been very receptive to sharing information in real time because their main goal is just that what the patients experience in real time on the ground mirrors their list. And so that is what they've been concerned about, both by talking to manufacturers, by talking to companies like Rowe. And so the more real-time data we can give them, the better off that they are.
31:52Lily and Novo, clearly, but there are differences in terms of how they deal with their supply issues. Can you speak to that? Absolutely. I think that what you see is the way that they're dealing with the shortage is pretty representative of the strategies, too. So, I mean, what they're doing similarly is they're both investing tremendously in ramping up the supply chain. But in terms of differently what they're doing, you see Novo, it's choking early titration doses. So it's harder to start but easier to maintain for people on the higher doses, which is essential to see those results. Really, you see it's easier to start.
32:22So 2.5 and 5 are available, but the higher doses aren't. So it's easier to start but harder to continue. And so you do see that. You also see Lilly actually getting approved single-dose vials, which will hopefully increase supply. But they are taking different strategies here. Talk to us a little bit. Obviously, these were diabetes drugs, and they moved into obesity. And you guys have spent a lot of time kind of demystifying or destigmatizing the obesity aspect of it. How are you guys thinking about this? And we are reporting, I guess, every day on different potential use cases. What are you most excited, I guess, away from obesity and obviously diabetes?
32:54Well, I think they aren't. To your point, they aren't just X drugs. They're not just diabetes drugs. They're not just obesity drugs or cardiovascular disease or kidney disease or sleep apnea. They're being studied for depression and addiction and Alzheimer's. So they aren't just X drugs. I think the really fascinating thing is we've been looking for a place or a universal wedge for consumer health care for a long time. And I think what you will see is GLP-1s really serve as the sun around which all other care will orbit because of their broad efficacy and the breadth of the label. But the stigma, to your point, the real impact that the stigma has is on those less fortunate because that impacts perception, which will impact employer coverage, government coverage, payer coverage.
33:34Whereas those with means, they are sort of unperturbed by the stigma and they'll pay for it. Hems and hers. Huge pop the other day on news that it's going to offer compounded GLP-1s through their site. You've got to be thinking about going public. Heisman is an investor, right? Rick is on all the time. Ricks investor, yes. GLP-1 adjacent, I mean, just like AI adjacent gets huge multiples. Yeah. So GLP-1 adjacent should be in theory too. Right now solely obsessed with helping our patients navigate the shortage, providing as many options as possible. And I think, you know, there will be a time, but right now it's just helping our patients navigate this.
34:11Good answer. That's a good answer. Well, you better come back to fast when it's time. All right, Zach, good to see you. Thank you. Thank you so much, Rob. Zach Ritano. I mean, this really just underscores the notion that you can't find these things and there's more and more demand and supply out there. I know. I mean, as you said, and he also said it, there's just more and more applications for it. We haven't even seen yet where it could be. I think a couple of months ago it was$80 billion, and now we're hearing like$100,$120 billion. Yeah, better understanding that mismatch between supply and demand really gives then the analyst community a chance to really get their numbers right.
34:47And that's just where we are now in the use cases we have. So fascinating. Coming up, a tale of two Tesla calls. Guggenheim and Piper Sandler at odds over where the easy maker stock is going next. Who's got it right? We'll debate that next. Plus, Roaring Kitty showing his cards. The meme stock general of Reddit revealing his position in GameStop. But did he just overplay his hand? The action from the options pits and beyond. Right after this, Fast Money is back in two.
35:18Welcome back to Fast Money. Tesla calls today laying out very different takes on the EV maker. Guggenheim reiterating its sell rating and$126 price target. That's 28 % lower from today's close. The firm saying Tesla's, quote, increasingly an investment underpinned by autonomy, which requires investors to buy into a vision of the future that has limited supporting evidence. On the other hand, Piper Sandler sticking with its overweight rating and$205 price target. Analysts noting they are looking beyond the June annual meeting where shareholders will vote on Musk's pay package. And while they are cutting their forecast for deliveries, they like to focus on AI and raise their margin forecast.
35:54The stock is down 1 % today, 30 % this year. I feel like everybody here is with Guggenheim on this one. Actually, I think they both can be right. I mean, we've seen rallies of that magnitude from 175 to 205. That's nothing in sort of the context of what the stock has done now for three years. It doesn't mean it's fixed. It doesn't mean it's necessarily bullish. but we have seen basically bounces off lows a number of times. Maybe we just saw it recently when it went from, what, 145 or so to 200. However, we've seen it before. With that said, I think you're right. I do favor the downside overall because for the last three and a half, four years, this has made a series of lower highs and lower lows.
36:37I wouldn't short it, though, right? I mean, I feel like there's asymmetric risk at this point to the upside. If for some reason FSD actually does happen and the margins are anywhere close, I think you'll see an enormous pop in the stock. All this other noise around Elon, the pay package, the chips, where do they go? All of that's just noise. Maybe it drifts lower on that, but the risk-reward towards shorting it, I wouldn't do it. But I don't know if it's just noise. Again, at least I realize Elon is the great grandstander. He is Barnum-Bailey and all of it wrapped up into one. But saying I don't really want to throw any of my resources, and I'm not even talking about the chips, but obviously unless I have 25%, I'm not going to focus on a place, you know, I'm going to put my AI and my robotics capabilities other places.
37:23This is why you've owned, you know, even before we were talking about AI every other second, this was why you owned Tesla. And when you hear this from the CEO, it has to be concerning at a time when I still think the dynamics around their core business mean it shouldn't trade at this multiple. Doesn't mean they're going out of business. Doesn't mean X. Doesn't mean Y. FSD is very important. It's just not worth this amount of money. All right. Coming up, game stopping. Bing. Shares of the retail are falling almost 4 % today. We'll get the read on what is ahead for the stock from the options pit.
37:53More Fast Money in two.
38:01We've got a news alert on the wireless outages affecting some AT &T, T-Mobile and Verizon customers. Let's get back to Contessa Brewer for the latest. Contessa. What you know is practically everybody. We have a statement now from the FCC on X, and they posted, we're aware of multiple states are unable to make wireless calls, and we are investigating. Apparently, there's been some hiccup between the ability of customers to make calls between carriers, like if you're calling from Verizon phone to an AT &T phone or an AT &T phone to a T-Mobile phone. And we heard earlier from AT &T saying there is a nationwide issue that's affecting the ability of customers to complete calls between carriers.
38:44The carriers are working to try to resolve the problem as quickly as possible to diagnose it as well. But we aren't sure who's the problem carrier here. All I know, Melissa, is that this afternoon, multiple times I've tried to use my phone and either I can't dial out or the call comes in and then it disappears. It's a problem for everybody. So I'm just glad that I was able to join you on Fast Money. We are, too, Contessa. Thank you, Contessa Brewer. Sure. Maybe that's why my phone didn't go off during the show. There's still time. Exactly. Maybe they'll fix it. All right. Meantime, GameStop shares are seeing a leg lower today, but still up more than 16, 18 percent, I should say, this week.
39:26The latest stock moves coming after Keith Gill, a.k.a. Roaring Kitty, started posting screenshots this week, presumably showing a substantial stake in the company. The most recent post showing a position of 5 million shares worth 140 million. And perhaps more interestingly,$120 ,020 call options that expire later this month. At the time of his post, he was up 76 % on those calls. But now that he's shown his cards, has he overplayed his hand? Mike Coe joins us with an answer to that question. Mike, what did you see in the options pits? Yeah, I mean, so this is a very interesting situation because if you take a look at that account fairly closely, one of the things you would recognize is that he has about$30 million in cash and 120 ,000 calls represents 12 million shares of stock times the$20 strike price.
40:12That's$240 million of funding. Now, the$30 million will certainly help take care of some of that, but it isn't sufficient for him to exercise all of those calls if the securities aren't marginable at E-Trade. So he is either going to have to sell some of those calls or he's going to have to sell all of his stock and then some, potentially going short against those calls sometime between now and June 21st, unless Keith Gill happens to have another couple hundred million dollars lying around that we're not seeing in some other account that he could transfer in to deal with that funding issue. So if you take a look at how much he has, how many of those calls he would have to sell, if that's the only thing he was going to sell, is going to depend on how much he can collect for them.
40:52So the lower the stock goes, the more of them he would have to sell to fund exercising the ones that he has not sold. And so interestingly, he's gotten himself into a little bit by tipping his hand into a little bit of a negative convexity position. But it could just be that he was trying to encourage others to rush in and buy the stock. He'll sell his five million, short the stock and do nothing with those calls and then just have the whole position take care of itself on June 21st. We'll see. Yep. And of course, as you mentioned, we don't know what his full position is. He showed one screenshot and who knows where else he's got money on other platforms.
41:27Mike, thank you for looking into this. Professor Coe, what do you make of all this? Mike's the man. You know, listen, depending on how convicted he is and how much capital he really has, he could roll them up and out. Like, for instance, he could actually, you know, go into a big bank and say, I want to roll these 120s. I want to go out to September. I want 30 strike calls, that sort of thing. And, you know, I mean, there's lots of things you could do. I just think, again, we don't know what he's doing. Yeah. What do you think he's doing? I think it's no good, I think. I think it's extraordinary.
41:57I mean, I'm still not really sure why you want to be long the stock. All right. Up next, final trades.
42:12Time for the final trade, Tim. That was some pullback in gold and therefore gold miners today. I think that GDX has weakness to buy. Karen. So, yeah, I looked at my bank position. I didn't want to change how much I had in banks, so I had to switch. I went from Morgan Stanley to Moore Citibank. We'll see you in five weeks when they report. Dan. Yeah, Carter had a great chart on Verizon. Looks like it's about to break out of a big downtrend. And also, to a woman who hasn't missed a show that I've been on for 15 years, Mary J. Nathan, happy birthday. Mrs. Nathan, happy birthday. That's a happy birthday right there.
42:46Would have been a happy Game 7, but... Guy? Walmart, Melissa Lee. Still goes higher. All right. Thank you for watching Fast Money. Join us back here at 5 tomorrow. Meantime, Mad Money with Jim Cramer starts right now.
43:21an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.
From the publisher
The traders lay out the one chart telling the real market story. How the levels and price action in these areas could detail where stocks head next. Plus One telehealth company launching a weight loss drug tracker, as the surge in popularity causes shortages. How they’re tipping the scales in the obesity drug wars.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
